Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of TLD, ED, and TLE for treatment-naive adults with HIV infection in Nigeria
PACTR202601637729258Phase 3Recruiting
- Sponsor
- AMA Pharmaceutical
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of tenofovir, lamivudine, dolutegravir and elsufavirine in human immunodeficiency virus infection (HIV) (3 arms), sponsored by AMA Pharmaceutical. Primary endpoints: Mean change in viral load, Viral suppression rate and 2 more. Started May 2025; status: recruiting.
02
Drugs
tenofovirlamivudinedolutegravirelsufavirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202601637729258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202601637729258.